ClinicalTrials.gg
Sign In

Drug

TGF-beta Receptor 1 Kinase Inhibitor YL-13027 clinical trials

Also written YL-13027.

studies test it
4
open now
1
in phase 3
0
first study started
2019

Keep track of what changes. Save the TGF-beta Receptor 1 Kinase Inhibitor YL-13027 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

YL-13027
4

Studies by the year they started

4 studies that test it; most in 2024 (2)

Studies that test TGF-beta Receptor 1 Kinase Inhibitor YL-13027, by start year
YearStudies
20191
20221
20242

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
1

What it is tested for

Each study’s main condition, where its own words name it.

Pancreatic Neoplasms
2
Neoplasms
2

Who runs them

Industry 3 · Other 1

Shanghai YingLi Pharmaceutical Co. Ltd. (3) · M.D. Anderson Cancer Center (1)

Often tested with

Tested in the same studies.

HY-0102 (1)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses TGF-beta Receptor 1 Kinase Inhibitor YL-13027 is read from its arms, and is right about nine times in ten.

Testing it · 4